Podcasts about psychiatry and mental health

Guest: Lauren Osborne, M.D. Lauren Osborne, M.D., a reproductive psychiatrist at NewYork-Presbyterian and Weill Cornell Medicine and vice chair for clinical research for the Department of Obstetrics and Gynecology, discusses her research into the biological basis of postpartum depression. In a recent study, Dr. Osborne and her team were the first to analyze the entire metabolic pathway of progesterone, measuring both positive and negative allosteric modulators of the GABAA receptor throughout pregnancy and ultimately identifying a potential biomarker to predict risk. They are continuing to study and build upon these findings, with the goal of enabling better prediction and treatment options to address, or even prevent, postpartum depression. © 2026 NewYork-Presbyterian

Host: Holly M. Brothers, PhD Guest: Niklas Mattsson-Carlgren, MD, PhD The prevalence of dementia is projected to almost double every 20 years.1 Alzheimer's disease (AD) is the most common cause of dementia,2 making early diagnosis and management increasingly important. Based on our current understanding of its pathology, AD is an amyloid driven tauopathy3 with biomarker changes occurring years before clinical symptoms appear.4 Learn more with this webinar featuring Dr Niklas Mattsson-Carlgren, Associate Professor at Lund University as he explores the relationship between amyloid beta and tau, the correlation between pathology and clinical symptoms, and biomarker progression across the AD continuum. To learn more about tau in Alzheimer's disease, explore the Know Tau medical education platform. Know Tau is created and funded by Biogen and is intended for healthcare professionals only. References: Alzheimer's Disease International. Numbers of people with dementia worldwide. Available from: https://www.alzint.org/resource/numbers-of-people-with-dementia-worldwide/ (Accessed June 2025) Alzheimer's Association. Alzheimer's disease facts and figures. Available from: https://www.alz.org/alzheimers-dementia/facts-figures (Accessed June 2025) Aksman LM, et al. Brain 2023;146:4935–4948 Jack CR Jr, et al. Alzheimers Dement 2018;14:535–562

Guest: Victoria Coleman-Cowger, PhD Gene therapy offers transformative potential for individuals with sickle cell disease, but the psychosocial challenges that accompany such a major decision are often underestimated. Hear from Dr. Victoria Coleman-Cowger as she highlights recommendations for supporting emotional wellbeing during and after gene therapy and explains the importance of recognizing both the psychological and social impacts of curative treatment. Dr. Coleman-Cowger is a licensed clinical psychologist and the Associate Vice President of Neurology and Cell and Gene Therapy at Emmes, a full-service clinical research foundation.

Guest: Victoria Coleman-Cowger, PhD Gene therapy offers transformative potential for individuals with sickle cell disease, but the psychosocial challenges that accompany such a major decision are often underestimated. Hear from Dr. Victoria Coleman-Cowger as she highlights recommendations for supporting emotional wellbeing during and after gene therapy and explains the importance of recognizing both the psychological and social impacts of curative treatment. Dr. Coleman-Cowger is a licensed clinical psychologist and the Associate Vice President of Neurology and Cell and Gene Therapy at Emmes, a full-service clinical research foundation.

CME credits: 0.25 Valid until: 02-12-2026 Claim your CME credit at https://reachmd.com/programs/cme/rethinking-schizophrenia-treatment-through-muscarinic-modulation/37103/ In this Chairperson's Perspective, Dr. Jose Rubio and Dr. Jonathan Meyer explore the evolving landscape of schizophrenia treatment through muscarinic receptor modulation. They compare the mechanisms of action, efficacy, and side effect profiles of muscarinic antipsychotics, such as xanomeline-trospium, with traditional dopamine D2 antagonists. The discussion addresses key clinical considerations for transitioning between dopaminergic and muscarinic therapies, including cholinergic burden and cross-titration timing. This expert dialogue provides relevant guidance for clinicians aiming to incorporate muscarinic therapies into personalized treatment plans for schizophrenia.=

CME credits: 0.50 Valid until: 07-11-2026 Claim your CME credit at https://reachmd.com/programs/cme/updates-in-major-depressive-disorder-with-insomnia/36556/ Approximately 75% to 90% of patients with depression experience insomnia. This means that a very significant portion of individuals struggling with depression also have difficulty sleeping. Join Drs. Michael Thase and Andrew Krystal for this expert discussion to learn about the most recent data presented at the Psych Congress 2025 in San Diego on emerging therapies, such as the selective OX2R antagonists to treat major depressive disorder with insomnia. =

CME credits: 0.25 Valid until: 30-10-2026 Claim your CME credit at https://reachmd.com/programs/cme/are-all-vmat2s-the-same-data-driven-treatment-decisions-for-tardive-dyskinesia/36174/ Tardive Dyskinesia (TD) is an involuntary movement disorder that can develop as a side effect of taking antipsychotic and other medications. Currently there are 2 FDA approved VMAT2 inhibitors for treating TD. Join Drs. Cristoph U. Correll and Jonathan M. Meyer for this expert discussion on the most recent data presented at the Psych Congress 2025 in San Diego on VMAT2 inhibitors for the treatment of TD.=

Host: Ryan Quigley New research presented at the 2025 American College of Rheumatology Convergence highlights a critical link between adverse childhood experiences and mental health outcomes in adolescents with childhood-onset systemic lupus erythematosus (cSLE). In this AudioAbstract, Ryan Quigley explores the findings, the implications for trauma-informed care, and the need to assess psychosocial history in managing cSLE.

Host: Ryan Quigley New research presented at the 2025 American College of Rheumatology Convergence highlights a critical link between adverse childhood experiences and mental health outcomes in adolescents with childhood-onset systemic lupus erythematosus (cSLE). In this AudioAbstract, Ryan Quigley explores the findings, the implications for trauma-informed care, and the need to assess psychosocial history in managing cSLE.

Host: Ryan Quigley Guest: Heather Forkey, MD Guest: Wynne Morgan, MD Childhood trauma can profoundly alter brain and behavioral development, making it essential to recognize how trauma differs from other diagnoses like ADHD. Ryan Quigley sits down with Drs. Heather Forkey and Wynne Morgan, who presented on this topic at the 2025 American Academy of Pediatrics National Conference and Exhibition, to better understand how to identify trauma responses, avoid misdiagnosis, and implement supportive treatment strategies that prioritize safety, routine, and caregiver connection. Dr. Forkey is a Professor of Pediatrics and Vice Chair of Pediatrics and Dr. Morgan is an Assistant Professor in the Departments of Psychiatry and Behavioral Sciences at UMass Chan Medical School in Worcester, Massachusetts.

Host: Ryan Quigley Guest: Heather Forkey, MD Guest: Wynne Morgan, MD Childhood trauma can profoundly alter brain and behavioral development, making it essential to recognize how trauma differs from other diagnoses like ADHD. Ryan Quigley sits down with Drs. Heather Forkey and Wynne Morgan, who presented on this topic at the 2025 American Academy of Pediatrics National Conference and Exhibition, to better understand how to identify trauma responses, avoid misdiagnosis, and implement supportive treatment strategies that prioritize safety, routine, and caregiver connection. Dr. Forkey is a Professor of Pediatrics and Vice Chair of Pediatrics and Dr. Morgan is an Assistant Professor in the Departments of Psychiatry and Behavioral Sciences at UMass Chan Medical School in Worcester, Massachusetts.

CME credits: 1.00 Valid until: 26-09-2026 Claim your CME credit at https://reachmd.com/programs/cme/from-resistance-to-response-evolving-strategies-in-mdd-management/32847/ Can you recognize the symptoms of major depressive disorder? Do you know when to augment and when to switch therapies? Join our experts for these answers and learn about novel treatments on the horizon. Don't miss this opportunity to enhance your clinical practice and positively impact the lives of your patients. =

CME credits: 0.50 Valid until: 09-07-2026 Claim your CME credit at https://reachmd.com/programs/cme/vns-beyond-seizure-control/35795/ This series of bite-sized episodes contains important information on using vagus nerve stimulation (VNS) for the treatment of drug-resistant epilepsy (DRE) and treatment-resistant depression (TRD). Drs. Raman Sankar and Scott Aaronson discuss best practices for identifying and treating patients as well as programming strategies for VNS.

CME credits: 0.50 Valid until: 09-07-2026 Claim your CME credit at https://reachmd.com/programs/cme/qol-matters-brain-stem-stimulation-in-patients-with-unipolar-depression/35796/ This series of bite-sized episodes contains important information on using vagus nerve stimulation (VNS) for the treatment of drug-resistant epilepsy (DRE) and treatment-resistant depression (TRD). Drs. Raman Sankar and Scott Aaronson discuss best practices for identifying and treating patients as well as programming strategies for VNS.

CME credits: 0.50 Valid until: 09-07-2026 Claim your CME credit at https://reachmd.com/programs/cme/optimizing-vns-parameters-keys-to-therapeutic-success/35797/ This series of bite-sized episodes contains important information on using vagus nerve stimulation (VNS) for the treatment of drug-resistant epilepsy (DRE) and treatment-resistant depression (TRD). Drs. Raman Sankar and Scott Aaronson discuss best practices for identifying and treating patients as well as programming strategies for VNS.

CME credits: 0.50 Valid until: 09-07-2026 Claim your CME credit at https://reachmd.com/programs/cme/differentiating-neuromodulation-therapies-vns-dbs-ect-tms/35793/ This series of bite-sized episodes contains important information on using vagus nerve stimulation (VNS) for the treatment of drug-resistant epilepsy (DRE) and treatment-resistant depression (TRD). Drs. Raman Sankar and Scott Aaronson discuss best practices for identifying and treating patients as well as programming strategies for VNS.

CME credits: 0.50 Valid until: 09-07-2026 Claim your CME credit at https://reachmd.com/programs/cme/differentiating-neuromodulation-therapies-vns-dbs-ect-tms/35793/ This series of bite-sized episodes contains important information on using vagus nerve stimulation (VNS) for the treatment of drug-resistant epilepsy (DRE) and treatment-resistant depression (TRD). Drs. Raman Sankar and Scott Aaronson discuss best practices for identifying and treating patients as well as programming strategies for VNS.

CME credits: 0.50 Valid until: 09-07-2026 Claim your CME credit at https://reachmd.com/programs/cme/epilepsy-beyond-seizure-impact/35794/ This series of bite-sized episodes contains important information on using vagus nerve stimulation (VNS) for the treatment of drug-resistant epilepsy (DRE) and treatment-resistant depression (TRD). Drs. Raman Sankar and Scott Aaronson discuss best practices for identifying and treating patients as well as programming strategies for VNS.

CME credits: 0.50 Valid until: 09-07-2026 Claim your CME credit at https://reachmd.com/programs/cme/vns-beyond-seizure-control/35795/ This series of bite-sized episodes contains important information on using vagus nerve stimulation (VNS) for the treatment of drug-resistant epilepsy (DRE) and treatment-resistant depression (TRD). Drs. Raman Sankar and Scott Aaronson discuss best practices for identifying and treating patients as well as programming strategies for VNS.

CME credits: 0.50 Valid until: 09-07-2026 Claim your CME credit at https://reachmd.com/programs/cme/qol-matters-brain-stem-stimulation-in-patients-with-unipolar-depression/35796/ This series of bite-sized episodes contains important information on using vagus nerve stimulation (VNS) for the treatment of drug-resistant epilepsy (DRE) and treatment-resistant depression (TRD). Drs. Raman Sankar and Scott Aaronson discuss best practices for identifying and treating patients as well as programming strategies for VNS.

CME credits: 0.50 Valid until: 09-07-2026 Claim your CME credit at https://reachmd.com/programs/cme/optimizing-vns-parameters-keys-to-therapeutic-success/35797/ This series of bite-sized episodes contains important information on using vagus nerve stimulation (VNS) for the treatment of drug-resistant epilepsy (DRE) and treatment-resistant depression (TRD). Drs. Raman Sankar and Scott Aaronson discuss best practices for identifying and treating patients as well as programming strategies for VNS.

CME credits: 0.50 Valid until: 09-07-2026 Claim your CME credit at https://reachmd.com/programs/cme/epilepsy-beyond-seizure-impact/35794/ This series of bite-sized episodes contains important information on using vagus nerve stimulation (VNS) for the treatment of drug-resistant epilepsy (DRE) and treatment-resistant depression (TRD). Drs. Raman Sankar and Scott Aaronson discuss best practices for identifying and treating patients as well as programming strategies for VNS.

Guest: John Golden Host: Michael Greenberg, MD Neuro-responsive EEG headphones are helping healthcare professionals combat burnout by promoting calm, focus, and resilience. Backed by neuroscience and real-time brain monitoring, this personalized technology blends music and neurofeedback to optimize mental states and reduce stress. Hear from Vital Neuro CEO John Golden as he joins Dr. Michael Greenberg to discuss this device's impact in clinical workflows, from pre-op anxiety management to enhanced physician well-being.

Guest: John Golden Guest: Michael Greenberg, MD EEG-guided headphones from Vital Neuro present a new frontier in anxiety management through personalized, real-time neurofeedback and music therapy. Dr. Michael Greenberg speaks with Vital Neuro CEO John Golden about the science behind these devices, their effectiveness in reducing anxiety symptoms, and how they can integrate into daily life.

Guest: John Golden Guest: Michael Greenberg, MD EEG-guided headphones from Vital Neuro present a new frontier in anxiety management through personalized, real-time neurofeedback and music therapy. Dr. Michael Greenberg speaks with Vital Neuro CEO John Golden about the science behind these devices, their effectiveness in reducing anxiety symptoms, and how they can integrate into daily life.

Guest: John Golden Host: Michael Greenberg, MD Neuro-responsive EEG headphones are helping healthcare professionals combat burnout by promoting calm, focus, and resilience. Backed by neuroscience and real-time brain monitoring, this personalized technology blends music and neurofeedback to optimize mental states and reduce stress. Hear from Vital Neuro CEO John Golden as he joins Dr. Michael Greenberg to discuss this device's impact in clinical workflows, from pre-op anxiety management to enhanced physician well-being.

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Ayman Al-Hendy, MD, PhD, FRCSC, FACOG, CCRP In addition to heavy menstrual bleeding, patients with uterine fibroids often deal with many other considerable effects on their physical and mental wellbeing. To provide optimal care, it's important to recognize the full impact of fibroids, communicate carefully about treatment options, and promote equitable access to care. Dr. Charles Turck sits down with Dr. Ayman Al-Hendy to learn more about how we can address the multifaceted burden of uterine fibroids. Dr. Al-Hendy is a Professor of Obstetrics and Gynecology and the Director of Translational Research at the University of Chicago Pritzker School of Medicine.

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Ayman Al-Hendy, MD, PhD, FRCSC, FACOG, CCRP In addition to heavy menstrual bleeding, patients with uterine fibroids often deal with many other considerable effects on their physical and mental wellbeing. To provide optimal care, it's important to recognize the full impact of fibroids, communicate carefully about treatment options, and promote equitable access to care. Dr. Charles Turck sits down with Dr. Ayman Al-Hendy to learn more about how we can address the multifaceted burden of uterine fibroids. Dr. Al-Hendy is a Professor of Obstetrics and Gynecology and the Director of Translational Research at the University of Chicago Pritzker School of Medicine.

CME credits: 0.50 Valid until: 31-01-2026 Claim your CME credit at https://reachmd.com/programs/cme/the-safety-of-sodium-oxybate-in-treating-narcolepsy/29457/ Sodium content and the disruption associated with the twice-nightly dosing of sodium oxybate are common concerns when treating patients with narcolepsy. Is sodium content truly a risk factor for cardiovascular sequelae in patients with narcolepsy? Does twice-nightly dosing lead to medically unacceptable dosing errors? Join Drs. Sally Ibrahim and Clete Kushida as they dive into these questions and provide actionable answers for you to use in your clinical practice.=

CME credits: 0.50 Valid until: 31-01-2026 Claim your CME credit at https://reachmd.com/programs/cme/the-safety-of-sodium-oxybate-in-treating-narcolepsy/29457/ Sodium content and the disruption associated with the twice-nightly dosing of sodium oxybate are common concerns when treating patients with narcolepsy. Is sodium content truly a risk factor for cardiovascular sequelae in patients with narcolepsy? Does twice-nightly dosing lead to medically unacceptable dosing errors? Join Drs. Sally Ibrahim and Clete Kushida as they dive into these questions and provide actionable answers for you to use in your clinical practice.=

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Sarah Shizuko Morimoto, PsyD Digital therapeutics are a rapidly developing type of treatment option across several therapeutic areas, including mental health. And while the technology is advancing rapidly, the science behind it needs time to catch up, so it's important to evaluate the supporting evidence when considering digital therapeutics for mental health.1 Joining Dr. Charles Turck to share her insights on how we can assess digital therapeutics is Dr. Sarah Shizuko Morimoto, Associate Professor of Population Health Sciences at the University of Utah in Salt Lake City. Reference: American Psychiatric Association. Accessed July 3, 2024. https://www.psychiatry.org/psychiatrists/practice/mental-health-apps/the-app-evaluation-model Dr. Morimoto is a paid consultant of Otsuka. November 2024 US.UNB.X.24.00100

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Robert McCarron, MD Guest: Arwen Podesta, MD Digital therapeutics are a relatively new and intriguing treatment option in mental health care but translating them from a clinical trial to clinical practice can be challenging. That's why Drs. Robert McCarron and Arwen Podesta join Dr. Charles Turck to share strategies for incorporating digital therapeutics into clinical practice. Dr. McCarron is a Professor in the Department of Psychiatry and Human Behavior at the University of California, Irvine School of Medicine, and Dr. Podesta is the President of the Louisiana Psychiatric Medical Association. Drs. McCarron and Podesta are consultants for Otsuka. September 2024 US.UNB.X.24.00073

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Maggie Emerson, DNP, APRN, PMHNP-BC Guiding patients and caregivers through the fast-moving landscape of digital therapeutics can be a challenging but worthwhile part of providing effective and accessible care. That's why Dr. Charles Turck speaks with Dr. Maggie Emerson about partnering with patients and caregivers around this relatively new treatment in mental health care. Dr. Emerson is a Clinical Associate Professor at the University of Nebraska Medical Center College of Nursing in Omaha. Dr. Emerson is a paid consultant of Otsuka. September 2024 US.UNB.X.24.00082

Guest: Jennifer L. Payne, MD Guest: Melissa Simon, MD Since postpartum depression is a serious medical condition that can negatively impact mothers, infants, and partners, it is important to identify symptoms in a timely manner.1-4 Dr. Jennifer Payne and Dr. Melissa Simon are here to share their clinical experiences screening patients for postpartum depression, explore strategies to overcome common challenges in screening, and identify best practices for collaborating in the care of perinatal women. Dr. Payne is a Professor of Psychiatry and Neurobehavioral Sciences as well as Obstetrics and Gynecology at the University of Virginia, and Dr. Simon is a Professor of Obstetrics and Gynecology at the Northwestern University Feinberg School of Medicine. References American Psychiatric Association. Depressive disorders. In: American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders: DSM-5™. 5th ed. American Psychiatric Publishing; 2013:155-188. Campbell SB, Cohn JF, Meyers T. Depression in First-Time Mothers: Mother-Infant Interaction and Depression Chronicity. Dev Psychol. 1995;31:349-357. Moore Simas TA, Huang MY, Patton C, et al. The humanistic burden of postpartum depression: a systematic literature review. Curr Med Res Opin. 2019;35(3):383-393. Thompson KS, Fox JE. Post-partum depression: a comprehensive approach to evaluation and treatment. Ment Health Fam Med. 2010;7(4):249-257. Sage Therapeutics and the Sage Therapeutics logo …

Host: Matt Birnholz, MD Guest: Jennifer L. Payne, MD Guest: Melissa Simon, MD Postpartum depression is a serious medical condition that is among the most common complications during and after pregnancy; however, it is often underdiagnosed.1-4 To learn more about screening patients for postpartum depression, Dr. Matt Birnholz speaks with Dr. Jennifer Payne and Dr. Melissa Simon about screening strategies, the impact of health inequities, and the latest medical guidelines regarding the importance of early screening for postpartum depression. Dr. Payne is a Professor of Psychiatry and Neurobehavioral Sciences as well as Obstetrics and Gynecology at the University of Virginia, and Dr. Simon is a Professor of Obstetrics and Gynecology at the Northwestern University Feinberg School of Medicine. References American Psychiatric Association. Depressive disorders. In: American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders: DSM-5™. 5th ed. American Psychiatric Publishing; 2013:155-188. Bauman BL, Ko JY, Cox S, et al. Vital Signs: Postpartum Depressive Symptoms and Provider Discussions About Perinatal Depression - United States, 2018. MMWR Morb Mortal Wkly Rep. 2020;69(19):575-581. Cox EQ, Sowa NA, Meltzer-Brody SE, Gaynes BN. The Perinatal Depression Treatment Cascade: Baby Steps Toward Improving Outcomes. J Clin Psychiatry. 2016;77(9):1189-1200. Thompson KS, Fox JE. Post-partum depression: a comprehensive approach to evaluation and treatment. Ment Health Fam Med. 2010;7(4):249-257. …

Guest: Jennifer L. Payne, MD Guest: Melissa Simon, MD Since postpartum depression is a serious medical condition that can negatively impact mothers, infants, and partners, it is important to identify symptoms in a timely manner.1-4 Dr. Jennifer Payne and Dr. Melissa Simon are here to share their clinical experiences screening patients for postpartum depression, explore strategies to overcome common challenges in screening, and identify best practices for collaborating in the care of perinatal women. Dr. Payne is a Professor of Psychiatry and Neurobehavioral Sciences as well as Obstetrics and Gynecology at the University of Virginia, and Dr. Simon is a Professor of Obstetrics and Gynecology at the Northwestern University Feinberg School of Medicine. References American Psychiatric Association. Depressive disorders. In: American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders: DSM-5™. 5th ed. American Psychiatric Publishing; 2013:155-188. Campbell SB, Cohn JF, Meyers T. Depression in First-Time Mothers: Mother-Infant Interaction and Depression Chronicity. Dev Psychol. 1995;31:349-357. Moore Simas TA, Huang MY, Patton C, et al. The humanistic burden of postpartum depression: a systematic literature review. Curr Med Res Opin. 2019;35(3):383-393. Thompson KS, Fox JE. Post-partum depression: a comprehensive approach to evaluation and treatment. Ment Health Fam Med. 2010;7(4):249-257. Sage Therapeutics and the Sage Therapeutics logo …

Host: Matt Birnholz, MD Guest: Jennifer L. Payne, MD Guest: Melissa Simon, MD Postpartum depression is a serious medical condition that is among the most common complications during and after pregnancy; however, it is often underdiagnosed.1-4 To learn more about screening patients for postpartum depression, Dr. Matt Birnholz speaks with Dr. Jennifer Payne and Dr. Melissa Simon about screening strategies, the impact of health inequities, and the latest medical guidelines regarding the importance of early screening for postpartum depression. Dr. Payne is a Professor of Psychiatry and Neurobehavioral Sciences as well as Obstetrics and Gynecology at the University of Virginia, and Dr. Simon is a Professor of Obstetrics and Gynecology at the Northwestern University Feinberg School of Medicine. References American Psychiatric Association. Depressive disorders. In: American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders: DSM-5™. 5th ed. American Psychiatric Publishing; 2013:155-188. Bauman BL, Ko JY, Cox S, et al. Vital Signs: Postpartum Depressive Symptoms and Provider Discussions About Perinatal Depression - United States, 2018. MMWR Morb Mortal Wkly Rep. 2020;69(19):575-581. Cox EQ, Sowa NA, Meltzer-Brody SE, Gaynes BN. The Perinatal Depression Treatment Cascade: Baby Steps Toward Improving Outcomes. J Clin Psychiatry. 2016;77(9):1189-1200. Thompson KS, Fox JE. Post-partum depression: a comprehensive approach to evaluation and treatment. Ment Health Fam Med. 2010;7(4):249-257. …

Host: Peter Buch, MD, FACG, AGAF, FACP Guest: Brian E. Lacy, MD, PhD About 50 percent of gastrointestinal providers are experiencing some degree of burnout, which can lead to a variety of personal and professional challenges. Joining Dr. Peter Buch to discuss the signs of burnout and what you can do to mitigate them is Dr. Brian Lacy, lead author of the “Burnout in Gastrointestinal Providers” article published in the American Journal of Gastroenterology in 2024.

Host: Peter Buch, MD, FACG, AGAF, FACP Guest: Brian E. Lacy, MD, PhD About 50 percent of gastrointestinal providers are experiencing some degree of burnout, which can lead to a variety of personal and professional challenges. Joining Dr. Peter Buch to discuss the signs of burnout and what you can do to mitigate them is Dr. Brian Lacy, lead author of the “Burnout in Gastrointestinal Providers” article published in the American Journal of Gastroenterology in 2024.

CME credits: 1.00 Valid until: 15-10-2025 Claim your CME credit at https://reachmd.com/programs/cme/role-of-pcp-ob-gyn-with-women-at-risk-for-ptsd-recognition-screening-and-referral/28621/ Patients with PTSD suffer from a range of psychiatric symptoms that severely reduce their quality of life. PTSD has proven to not only be a complicated diagnosis, but also one that has a low index of suspicion. Many patients are not screened for PTSD, and those who are diagnosed often gain little benefit from currently available treatments. Join us as these issues are dissected by Drs. Joseph Goldberg and Roger McIntyre, with the objective of providing clinicians with key action steps to take to improve outcomes for patients affected by PTSD.

CME credits: 1.00 Valid until: 15-10-2025 Claim your CME credit at https://reachmd.com/programs/cme/setting-the-stage-unmet-needs-in-the-treatment-of-women-with-ptsd/28618/ Patients with PTSD suffer from a range of psychiatric symptoms that severely reduce their quality of life. PTSD has proven to not only be a complicated diagnosis, but also one that has a low index of suspicion. Many patients are not screened for PTSD, and those who are diagnosed often gain little benefit from currently available treatments. Join us as these issues are dissected by Drs. Joseph Goldberg and Roger McIntyre, with the objective of providing clinicians with key action steps to take to improve outcomes for patients affected by PTSD.

CME credits: 1.00 Valid until: 15-10-2025 Claim your CME credit at https://reachmd.com/programs/cme/prevalence-and-burden-of-ptsd-in-women-focus-on-factors-that-affect-patient-presentation-such-as-race-risk-factors-stigma-and-other-drivers/28620/ Patients with PTSD suffer from a range of psychiatric symptoms that severely reduce their quality of life. PTSD has proven to not only be a complicated diagnosis, but also one that has a low index of suspicion. Many patients are not screened for PTSD, and those who are diagnosed often gain little benefit from currently available treatments. Join us as these issues are dissected by Drs. Joseph Goldberg and Roger McIntyre, with the objective of providing clinicians with key action steps to take to improve outcomes for patients affected by PTSD.

CME credits: 1.00 Valid until: 15-10-2025 Claim your CME credit at https://reachmd.com/programs/cme/proactively-uncovering-potential-traumatic-experiences-linked-to-patient-psychiatric-symptoms-in-women/28622/ Patients with PTSD suffer from a range of psychiatric symptoms that severely reduce their quality of life. PTSD has proven to not only be a complicated diagnosis, but also one that has a low index of suspicion. Many patients are not screened for PTSD, and those who are diagnosed often gain little benefit from currently available treatments. Join us as these issues are dissected by Drs. Joseph Goldberg and Roger McIntyre, with the objective of providing clinicians with key action steps to take to improve outcomes for patients affected by PTSD.

CME credits: 1.00 Valid until: 15-10-2025 Claim your CME credit at https://reachmd.com/programs/cme/conversations-with-patients-about-ptsd-screening-and-referral/28623/ Patients with PTSD suffer from a range of psychiatric symptoms that severely reduce their quality of life. PTSD has proven to not only be a complicated diagnosis, but also one that has a low index of suspicion. Many patients are not screened for PTSD, and those who are diagnosed often gain little benefit from currently available treatments. Join us as these issues are dissected by Drs. Joseph Goldberg and Roger McIntyre, with the objective of providing clinicians with key action steps to take to improve outcomes for patients affected by PTSD.

CME credits: 1.00 Valid until: 15-10-2025 Claim your CME credit at https://reachmd.com/programs/cme/inconsistent-outcomes-how-ignoring-guidelines-leads-to-unpredictable-results/28624/ Patients with PTSD suffer from a range of psychiatric symptoms that severely reduce their quality of life. PTSD has proven to not only be a complicated diagnosis, but also one that has a low index of suspicion. Many patients are not screened for PTSD, and those who are diagnosed often gain little benefit from currently available treatments. Join us as these issues are dissected by Drs. Joseph Goldberg and Roger McIntyre, with the objective of providing clinicians with key action steps to take to improve outcomes for patients affected by PTSD.

CME credits: 1.00 Valid until: 15-10-2025 Claim your CME credit at https://reachmd.com/programs/cme/limitations-of-current-treatments-fda-approved-and-off-label-approaches/28625/ Patients with PTSD suffer from a range of psychiatric symptoms that severely reduce their quality of life. PTSD has proven to not only be a complicated diagnosis, but also one that has a low index of suspicion. Many patients are not screened for PTSD, and those who are diagnosed often gain little benefit from currently available treatments. Join us as these issues are dissected by Drs. Joseph Goldberg and Roger McIntyre, with the objective of providing clinicians with key action steps to take to improve outcomes for patients affected by PTSD.

CME credits: 1.00 Valid until: 15-10-2025 Claim your CME credit at https://reachmd.com/programs/cme/pathophysiology-and-pharmacologic-rationale-of-emerging-agents-for-the-treatment-of-ptsd/28626/ Patients with PTSD suffer from a range of psychiatric symptoms that severely reduce their quality of life. PTSD has proven to not only be a complicated diagnosis, but also one that has a low index of suspicion. Many patients are not screened for PTSD, and those who are diagnosed often gain little benefit from currently available treatments. Join us as these issues are dissected by Drs. Joseph Goldberg and Roger McIntyre, with the objective of providing clinicians with key action steps to take to improve outcomes for patients affected by PTSD.

CME credits: 1.00 Valid until: 15-10-2025 Claim your CME credit at https://reachmd.com/programs/cme/profile-and-role-of-emerging-treatment-options-moa-safety-and-efficacy-and-identifying-the-patients-who-may-benefit/28627/ Patients with PTSD suffer from a range of psychiatric symptoms that severely reduce their quality of life. PTSD has proven to not only be a complicated diagnosis, but also one that has a low index of suspicion. Many patients are not screened for PTSD, and those who are diagnosed often gain little benefit from currently available treatments. Join us as these issues are dissected by Drs. Joseph Goldberg and Roger McIntyre, with the objective of providing clinicians with key action steps to take to improve outcomes for patients affected by PTSD.

CME credits: 1.00 Valid until: 15-10-2025 Claim your CME credit at https://reachmd.com/programs/cme/modeling-activity-quality-conversations-with-patients-about-suboptimal-management-of-ptsd-symptoms-and-emerging-treatment-options/28647/ Patients with PTSD suffer from a range of psychiatric symptoms that severely reduce their quality of life. PTSD has proven to not only be a complicated diagnosis, but also one that has a low index of suspicion. Many patients are not screened for PTSD, and those who are diagnosed often gain little benefit from currently available treatments. Join us as these issues are dissected by Drs. Joseph Goldberg and Roger McIntyre, with the objective of providing clinicians with key action steps to take to improve outcomes for patients affected by PTSD.

Host: Matt Birnholz, MD Guest: Kay Matthews, LCHW Ms. Kay Matthews has lived experience with postpartum depression and now advocates for others as the Executive Director and Founder of Shades of Blue, which is dedicated to breaking cultural barriers in maternal mental health. Tune in to hear her speak with Dr. Matt Birnholz about her journey with postpartum depression, barriers that can prevent or delay patients from seeking care, and strategies for combatting stigma and ensuring a timely diagnosis. Sage Therapeutics and the Sage Therapeutics logo are registered trademarks of Sage Therapeutics, Inc.Sage Therapeutics, Inc. All rights reserved.Sage Therapeutics ©2024 MRC-PPD-00792 06/2024